Jump to contents

Researcher Information

last modified:2021/03/29

Associate Professor TAKESHITA, Yumie

Faculty, Affiliation

Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences Kanazawa University Hospital

College and School Educational Field


Laboratory

Kanazawa University Hospital

Academic Background

Career

Year & Month of Birth

Academic Society

The Japan Endocrine Society
The Japan Diabetes Society
Japanese Society of Internal Medicine

Award

Specialities

Gastroenterology、Metabolomics

Speciality Keywords

Diabetes Endocrinology non-alcoholic hepatitis

Research Themes

Books

  •  Yumie Takeshita  Capter D: Public Health of viral Hepatitis Hepatitis 2019
  •  Yumie Takeshita Capter A: Non-Alcoholic Fatty Liver Disease 3 3.Treatment of NAFLD Non-Alcoholic Fatty Liver Disease 2019
  •  Yumie Takeshita  Capter A: Non-Alcoholic Fatty Liver Disease Non-Alcoholic Fatty Liver Disease 1 2019

Papers

  •  Alcohol Intake Is Associated With Elevated Serum Levels of Selenium and Selenoprotein P in Humans. Isobe Y, Asakura H, Tsujiguchi H, Kannon T, Takayama H, Takeshita Y, Ishii KA, Kanamori T, Hara A, Yamashita T, Tajima A, Kaneko S, Nakamura H, Takamura T. Front Nutr. 22 8 633703 2021/02/22
  •  LECT2 as a hepatokine links liver steatosis to inflammation via activating tissue macrophages in NASH. Takata N, Ishii KA, Takayama H, Nagashimada M, Kamoshita K, Tanaka T, Kikuchi A, Takeshita Y, Matsumoto Y, Ota T, Yamamoto Y, Yamagoe S, Seki A, Sakai Y, Kaneko S, Takamura T. Sci Rep. 12 11 555 2021/01/12
  •  Metabolic and sympathovagal effects of bolus insulin glulisine versus basal insulin glargine therapy in people with type 2 diabetes: A randomized controlled study. Takeshita Y, Tanaka T, Wakakuri H, Kita Y, Kanamori T, Takamura T. J Diabetes Investig.  2020/11/29
  •  Study Protocol for Pleiotropic Effects and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Versus Sulfonylurea in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. Takeshita Y, Kanamori T, Tanaka T, Kaikoi Y, Kita Y, Takata N, Iida N, Arai K, Yamashita T, Harada K, Gabata T, Nakamura H, Kaneko S, Takamura T.  Diabetes Ther. 11 549-560 2020/02
  •  Induction of Selenoprotein P mRNA during Hepatitis C Virus Infection Inhibits RIG-I-Mediated Antiviral Immunity. Murai K, Honda M, Shirasaki T, Shimakami T, Omura H, Misu H, Kita Y, Takeshita Y, Ishii KA, Takamura T, Urabe T, Shimizu R, Okada H, Yamashita T, Sakai Y, Kaneko S. Cell Host Microbe. 10 25 588-601 2019/04/10

show all

  •   A novel PHEX mutation associated with vitamin D-resistant rickets. Sako S, Niida Y, Shima KR, Takeshita Y, Ishii KA, Takamura T. Hum Genome Var. 2019 6 9 2019/02/14
  •  Circulating concentrations of insulin resistance-associated hepatokines, selenoprotein P and leukocyte cell-derived chemotaxin 2, during an oral glucose tolerance test in humans.  Mohri K, Misu H, Takayama H, Ishii KA, Kikuchi A, Lan F, Enyama Y, Takeshita Y, Saito Y, Kaneko S, Takamura T. Biol Pharm Bull. 42 3 373-378 2018/12/28
  •  Mealtime dosing of a rapid-acting insulin analog reduces glucose variability and suppresses daytime cardiac sympathetic activity: a randomized controlled study in hospitalized patients with type 2 diabetes. Kanamori T, Takeshita Y, Isobe Y, Kato KI, Misu H, Kaneko S, Takamura T. BMJ Open Diabetes Res Care. 6 1 e000588 2018/10/31
  •  Serum selenoprotein P, but not selenium, predicts future hyperglycemia in a general Japanese population Oo SM, Misu H, Saito Y, Tanaka M, Kato S, Kita Y, Takayama H, Takeshita Y, Kanamori T, Nagano T, Nakagen M, Urabe T, Matsuyama N, Kaneko S, Takamura T Sci Rep.  8 1 16727 2018/11/13
  •  Consuming Carbohydrates after Meat or Vegetables Lowers Postprandial Excursions of Glucose and Insulin in Nondiabetic Subjects. Nishino K, Sakurai M, Takeshita Y, Takamura T. J Nutr Sci Vitaminol. 64 5 316-320 2018
  •  Vanishing of ruptured adrenal mass with takotsubo cardiomyopathy. Takeshita Y, Teramura C, Takamura T. Endocr J. 65 12 1155-1159 2018/12/28
  •  Effects of metformin and alogliptin on body composition in people with type 2 diabetes. Takeshita Y, Kita Y, Kato KI, Kanamori T, Misu H, Kaneko S, Takamura T. J Diabetes Investig. 10 3 723-730 2019/05/10
  •  Ursodeoxycholic acid potentiates dipeptidyl peptidase-4 inhibitor sitagliptin by enhancing glucagon-like peptide-1 secretion in patients with type 2 diabetes and chronic liver disease: a pilot randomized controlled and add-on study. Shima KR, Ota T, Kato KI, Takeshita Y, Misu H, Kaneko S, Takamura T BMJ Open Diabetes Res Care. 6 1 e000469 2018/06
  •  Corrigendum to 'Weight-adjusted lean body mass and calf circumference are protective against obesity-associated insulin resistance and metabolic abnormalities'. Takamura T, Kita Y, Nakagen M, Sakurai M, Isobe Y, Takeshita Y, Kawai K, Urabe T, Kaneko S. Heliyon. 26 3 e00363 2017/07/07
  •  Weight-adjusted lean body mass and calf circumference are protective against obesity-associated insulin resistance and metabolic abnormalities. Takamura T, Kita Y, Nakagen M, Sakurai M, Isobe Y, Takeshita Y, Kawai K, Urabe T, Kaneko S. Heliyon. 3 7 e00347 2017/07/04
  •  Eicosapentaenoic acid down-regulates expression of the selenoprotein P gene by inhibiting SREBP-1c protein independently of the AMP-activated protein kinase pathway in H4IIEC3 hepatocytes. Tajima-Shirasaki N, Ishii KA, Takayama H, Shirasaki T, Iwama H, Chikamoto K, Saito Y, Iwasaki Y, Teraguchi A, Lan F, Kikuchi A, Takeshita Y, Murao K, Matsugo S, Kaneko S, Misu H, Takamura T. J Biol Chem. 292 26 10791-10800 2017/06/30
  •  Deficiency of the hepatokine selenoprotein P increases responsiveness to exercise in mice through upregulation of reactive oxygen species and AMP-activated protein kinase in muscle. Misu H, Takayama H, Saito Y, Mita Y, Kikuchi A, Ishii KA, Chikamoto K, Kanamori T, Tajima N, Lan F, Takeshita Y, Honda M, Tanaka M, Kato S, Matsuyama N, Yoshioka Y, Iwayama K, Tokuyama K, Akazawa N, Maeda S, Takekoshi K, Matsugo S, Noguchi N, Kaneko S, Takamura T.  Nat Med.  23 4 508-516 2017/02/27
  •  Rapid response of the steatosis-sensing hepatokine LECT2 during diet-induced weight cycling in mice. Chikamoto K, Misu H, Takayama H, Kikuchi A, Ishii KA, Lan F, Takata N, Tajima-Shirasaki N, Takeshita Y, Tsugane H, Kaneko S, Matsugo S, Takamura T.  Biochem Biophys Res Commun.  478 3 1310-1316 2016/09/23
  •  Altered gene expression in T-cell receptor signalling in peripheral blood leucocytes in acute coronary syndrome predicts secondary coronary events. Takashima S, Usui S, Kurokawa K, Kitano T, Kato T, Murai H, Furusho H, Oda H, Maruyama M, Nagata Y, Usuda K, Kubota K, Takeshita Y, Sakai Y, Honda M, Kaneko S, Takamura M.  Open Heart.  3 1 e000400 2016/06/30
  •  Fat-free mass and calf circumference as body composition indices to determine non-exercise activity thermogenesis in patients with diabetes. Isobe Y, Sakurai M, Kita Y, Takeshita Y, Misu H, Kaneko S, Takamura T.  J Diabetes Investig.  7 3 352-358 2016/05
  •  Pleiotropic effects of sitagliptin versus voglibose in patients with type 2 diabetes inadequately controlled via diet and/or a single oral antihyperglycemic agent: a multicenter, randomized trial.  Matsushima Y, Takeshita Y, Kita Y, Otoda T, Kato K, Toyama-Wakakuri H, Akahori H, Shimizu A, Hamaguchi E, Nishimura Y, Kanamori T, Kaneko S, Takamura T.  BMJ Open Diabetes Res Care.  4 1 e000190 2016/04/19
  •  Bending of a vertical cannula without alarm during insulin pump therapy as a cause of unexpected hyperglycemia: A Japanese issue? Kuroda K, Takeshita Y, Kaneko S, Takamura T J Diabetes Investig. 6 6 739-740 2015/11/06
  •  Sitagliptin versus mitiglinide switched from mealtime dosing of a rapid-acting insulin analog in patients with type 2 diabetes: a randomized, parallel-group study. Takeshita Y, Takamura T, Kita Y, Takazakura A, Kato K, Isobe Y, Kaneko S. BMJ Open Diabetes Res Care. 3 1 e000122. 2015/08/28
  •  Renoprotective effects of atorvastatin compared with pravastatin on progression of early diabetic nephropathy. Takazakura A, Sakurai M, Bando Y, Misu H, Takeshita Y, Kita Y, Shimizu A, Hayakawa T, Kato K, Kaneko S, Takamura T. J Diabetes Investig.  6 3 346-353 2015/05/06
  •  Vildagliptin vs liraglutide as a second-line therapy switched from sitagliptin-based regimens in patients with type 2 diabetes: A randomized, parallel-group study. Takeshita Y, Takamura T, Kita Y, Otoda T, Kato K, Wakakuri H, Yamada M, Misu H, Matsushima Y, Kaneko S; Establishment of Rationale for Antiaging Diabetic Medicine (ERA-DM) Study Chapter 2 Group J Diabetes Investig.  6 2 192-200 2015/03/06
  •  Liver steatosis is associated with insulin resistance in skeletal muscle rather than in the liver in Japanese patients with non-alcoholic fatty liver disease. Kato K, Takeshita Y, Misu H, Zen Y, Kaneko S, Takamura T. J Diabetes Investig.  6 2 158-163 2015/03/06
  •  Development of a Sol Particle Homogeneous Immunoassay for Measuring Full-Length Selenoprotein P in Human Serum. Tanaka M, Saito Y, Misu H, Kato S, Kita Y, Takeshita Y, Kanamori T, Nagano T, Nakagen M, Urabe T, Takamura T, Kaneko S, Takahashi K, Matsuyama N. J Clin Lab Anal. 30 2 114-122 2016/03/30
  •  Response to Importance of confounding factors in assessing fatty acid compositions in patients with non-alcoholic steatohepatitis. Yamada K, Mizukoshi E, Sunagozaka H, Arai K, Yamashita T, Takeshita Y, Misu H, Takamura T, Kitamura S, Zen Y, Nakanuma Y, Honda M, Kaneko S Liver Int. 35 6 1773 2015/06
  •  Characteristics of hepatic fatty acid compositions in patients with nonalcoholic steatohepatitis. Yamada K, Mizukoshi E, Sunagozaka H, Arai K, Yamashita T, Takeshita Y, Misu H, Takamura T, Kitamura S, Zen Y, Nakanuma Y, Honda M, Kaneko S. Liver Int. 35 2 582-590 2015/02
  •  Selenoprotein P as a diabetes-associated hepatokine that impairs angiogenesis by inducing VEGF resistance in vascular endothelial cells. Ishikura K, Misu H, Kumazaki M, Takayama H, Matsuzawa-Nagata N, Tajima N, Chikamoto K, Lan F, Ando H, Ota T, Sakurai M, Takeshita Y, Kato K, Fujimura A, Miyamoto K, Saito Y, Kameo S, Okamoto Y, Takuwa Y, Takahashi K, Kidoya H, Takakura N, Kaneko S, Takamura T Diabetologia. 57 9 1968-1976 2014/09
  •  Urinary Kim-1 is a sensitive biomarker for the early stage of diabetic nephropathy in Otsuka Long-Evans Tokushima Fatty rats. Hosohata K, Ando H, Takeshita Y, Misu H, Takamura T, Kaneko S, Fujimura A. Diab Vasc Dis Res. 11 4 243-250 2014/07
  •  Ectopic fat accumulation and distant organ-specific insulin resistance in Japanese people with nonalcoholic fatty liver disease. Kato K, Takamura T, Takeshita Y, Ryu Y, Misu H, Ota T, Tokuyama K, Nagasaka S, Matsuhisa M, Matsui O, Kaneko S. PLoS One. 9 3 e92170. 2014/03/20
  •  LECT2 functions as a hepatokine that links obesity to skeletal muscle insulin resistance. Lan F, Misu H, Chikamoto K, Takayama H, Kikuchi A, Mohri K, Takata N, Hayashi H, Matsuzawa-Nagata N, Takeshita Y, Noda H, Matsumoto Y, Ota T, Nagano T, Nakagen M, Miyamoto K, Takatsuki K, Seo T, Iwayama K, Tokuyama K, Matsugo S, Tang H, Saito Y, Yamagoe S, Kaneko S, Takamura T. Diabetes. 63 5 1649-1664 2014/05
  •  The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial. Takeshita Y, Takamura T, Honda M, Kita Y, Zen Y, Kato K, Misu H, Ota T, Nakamura M, Yamada K, Sunagozaka H, Arai K, Yamashita T, Mizukoshi E, Kaneko S Diabetologia. 57 5 878-890 2014/05
  •  Quantitative analysis of hepatic fat fraction by single-breath-holding MR spectroscopy with T₂ correction: phantom and clinical study with histologic assessment. Hayashi N, Miyati T, Minami T, Takeshita Y, Ryu Y, Matsuda T, Ohno N, Hamaguchi T, Kato K, Takamura T, Matsui O. Radiol Phys Technol. 6 1 219-225 2013/06
  •  Proteasome dysfunction mediates obesity-induced endoplasmic reticulum stress and insulin resistance in the liver. Otoda T, Takamura T, Misu H, Ota T, Murata S, Hayashi H, Takayama H, Kikuchi A, Kanamori T, Shima KR, Lan F, Takeda T, Kurita S, Ishikura K, Kita Y, Iwayama K, Kato K, Uno M, Takeshita Y, Yamamoto M, Tokuyama K, Iseki S, Tanaka K, Kaneko S. Diabetes. 62 3 811-824 2013/03
  •  Metformin prevents and reverses inflammation in a non-diabetic mouse model of nonalcoholic steatohepatitis. Kita Y, Takamura T, Misu H, Ota T, Kurita S, Takeshita Y, Uno M, Matsuzawa-Nagata N, Kato K, Ando H, Fujimura A, Hayashi K, Kimura T, Ni Y, Otoda T, Miyamoto K, Zen Y, Nakanuma Y, Kaneko S. PLoS One. 7 9 e43056 2012/07
  •  Duodenal adenocarcinoma with neuroendocrine features in a patient with acromegaly and thyroid papillary adenocarcinoma: a unique combination of endocrine neoplasia. Kato K, Takeshita Y, Misu H, Ishikura K, Kakinoki K, Sawada-Kitamura S, Kaneko S, Takamura T. Endocr J. 59 9 791-796 2012
  •  Pharmacokinetics and pharmacodynamics of insulin aspart in patients with type 2 diabetes: assessment using a meal tolerance test under clinical conditions. Ando H, Kurita S, Shimizu A, Kato K, Ishikura K, Taji K, Uno M, Takeshita Y, Misu H, Fujimura A, Kaneko S, Takamura T. Clin Exp Pharmacol Physiol. 39 6 528-534 2012/06
  •  Beneficial effect of branched-chain amino acid supplementation on glycemic control in chronic hepatitis C patients with insulin resistance: implications for type 2 diabetes. Takeshita Y, Takamura T, Kita Y, Ando H, Ueda T, Kato K, Misu H, Sunagozaka H, Sakai Y, Yamashita T, Mizukoshi E, Honda M, Kaneko S. Metabolism. 61 10 1388-1394 2012/10
  •  Inverse correlation between serum levels of selenoprotein P and adiponectin in patients with type 2 diabetes. Misu H, Ishikura K, Kurita S, Takeshita Y, Ota T, Saito Y, Takahashi K, Kaneko S, Takamura T. PLoS One. 7 4 e34952. 2012/07
  •  Identification of blood biomarkers of aging by transcript profiling of whole blood. Nakamura S, Kawai K, Takeshita Y, Honda M, Takamura T, Kaneko S, Matoba R, Matsubara K. Biochem Biophys Res Commun. 418 2 313-318 2012/02/10
  •  Slowly progressive insulin-dependent diabetes in a patient with primary biliary cirrhosis with portal hypertension-type progression. Takeshita Y, Takamura T, Inoue O, Okumura M, Kato K, Sunagozaka H, Arai K, Misu H, Nakamura M, Nakanuma Y, Kaneko S. Intern Med. 51 1 79-82 2012
  •  Graves' disease associated with infectious mononucleosis due to primary Epstein-Barr virus infection: report of 3 cases. Akahori H, Takeshita Y, Saito R, Kaneko S, Takamura T. Intern Med. 49 23 2599-2603 2010
  •  A liver-derived secretory protein, selenoprotein P, causes insulin resistance. Misu H, Takamura T, Takayama H, Hayashi H, Matsuzawa-Nagata N, Kurita S, Ishikura K, Ando H, Takeshita Y, Ota T, Sakurai M, Yamashita T, Mizukoshi E, Yamashita T, Honda M, Miyamoto K, Kubota T, Kubota N, Kadowaki T, Kim HJ, Lee IK, Minokoshi Y, Saito Y, Takahashi K, Yamada Y, Takakura N, Kaneko S. Cell Metab. 12 5 483-495 2010/11/03
  •  Effect of pioglitazone on muscle sympathetic nerve activity in type 2 diabetes mellitus with α-glucosidase inhibitor. Kobayashi D, Takamura M, Murai H, Usui S, Ikeda T, Inomata J, Takashima S, Kato T, Furusho H, Takeshita Y, Ota T, Takamura T, Kaneko S. Auton Neurosci.  158 1-2 86-91 2010/12/08
  •  Cushing's syndrome and big IGF-II associated hypoglycaemia in a patient with adrenocortical carcinoma. Ishikura K, Takamura T, Takeshita Y, Nakagawa A, Imaizumi N, Misu H, Taji K, Kasahara K, Oshinoya Y, Suzuki S, Ooi A, Kaneko S. BMJ Case Rep.  bcr07.2009.2100. 2010/03/30
  •  Histological course of nonalcoholic fatty liver disease in Japanese patients: tight glycemic control, rather than weight reduction, ameliorates liver fibrosis. Hamaguchi E, Takamura T, Sakurai M, Mizukoshi E, Zen Y, Takeshita Y, Kurita S, Arai K, Yamashita T, Sasaki M, Nakanuma Y, Kaneko S. Diabetes Care. 33 2 284-286 2010/02
  •  Obesity upregulates genes involved in oxidative phosphorylation in livers of diabetic patients. Takamura T, Misu H, Matsuzawa-Nagata N, Sakurai M, Ota T, Shimizu A, Kurita S, Takeshita Y, Ando H, Honda M, Kaneko S. Obesity 16 12 2601-2609 2008/12
  •  Transformation of p53-positive papillary thyroid carcinoma to anaplastic carcinoma of the liver following postoperative radioactive iodine-131 therapy. Takeshita Y, Takamura T, Minato H, Misu H, Ando H, Yamashita T, Ikeda H, Nakanuma Y, Kaneko S. Intern Med. 47 19 1709-1712 2008
  •  Cross talk of tumor necrosis factor-alpha and the renin-angiotensin system in tumor necrosis factor-alpha-induced plasminogen activator inhibitor-1 production from hepatocytes. Takeshita Y, Takamura T, Ando H, Hamaguchi E, Takazakura A, Matsuzawa-Nagata N, Kaneko S. Eur J Pharmacol. 579 1-3 426-432 2008/01/28
  •  Regulation of adiponectin receptor expression in human liver and a hepatocyte cell line. Shimizu A, Takamura T, Matsuzawa N, Nakamura S, Nabemoto S, Takeshita Y, Misu H, Kurita S, Sakurai M, Yokoyama M, Zen Y, Sasaki M, Nakanuma Y, Kaneko S. Metabolism.  56 11 1478-1485 2007/11
  •  Factors associated with improvement of fasting plasma glucose level by mealtime dosing of a rapid-acting insulin analog in type 2 diabetes. Takamura T, Sakurai M, Nakamura M, Shimizu A, Ota T, Misu H, Takeshita Y, Tsuchiyama N, Kurita S, Ando H, Kaneko S. Diabetes Res Clin Pract. 75 3 278-284 2007/03
  •  Tumor necrosis factor-alpha-induced production of plasminogen activator inhibitor 1 and its regulation by pioglitazone and cerivastatin in a nonmalignant human hepatocyte cell line. Takeshita Y, Takamura T, Hamaguchi E, Shimizu A, Ota T, Sakurai M, Kaneko S. Metabolism. 55 11 1464-1472 2006/11
  •  Relationship between plasma hANP level and pretibial edema by pioglitazone treatment. Kahara T, Takamura T, Misaki T, Sakurai M, Takeshita Y, Shimizu A, Kaneko S. Endocr J. 52 3 373-376 2005/06

Conference Presentations

Others

Arts and Fieldwork

Patent

Theme to the desired joint research

Grant-in-Aid for Scientific Research

Competitive research funding,Contribution

Collaborative research,Consignment study

Classes (Bachelors)

○Diabetes (2020)
○Diabetes (2020)
○Global report on diabetes(2020)
○10秒にひとりの命を奪う病  糖尿病とどう闘うか? (2020)
○Treatment for diabetes(2019)
○Diabetes (2019)

Classes (Graduate Schools)

○Disease Control and Homeotasis(2020)
○Comprehensive Metabology(2020)
○Disease Control and Homeotasis(2020)
○Comprehensive Metabology(2020)
○Preventive Medicine(2020)
○Environment and Health(2020)
○Comprehensive Metabology(2019)
○Disease Control and Homeotasis(2019)
○Disease Control and Homeotasis(2019)
○Preventive Medicine(2019)
○Comprehensive Metabology(2019)
○Disease Control and Homeotasis(2018)
○Disease Control and Homeotasis(2018)
○Comprehensive Metabology(2018)
○Comprehensive Metabology(2018)
○Comprehensive Metabology(2017)
○Disease Control and Homeotasis(2017)
○Disease Control and Homeotasis(2017)
○Comprehensive Metabology(2017)
○Disease Control and Homeotasis(2017)
○Disease Control and Homeotasis(2017)
○Comprehensive Metabology(2017)
○Comprehensive Metabology(2017)

International Project

International Students

Lecture themes

Others (Social Activities)

To Page Top